###### Strengths and limitations of this study

-   A unique methodology was developed to collect costing data in low socioeconomic settings.

-   This methodology could be replicated in similar countries with high prevalence of oral cancer.

-   Arbitrary depreciation and personnel rates were taken due to unavailability of government validated costing algorithms.

-   Cost calculations could be incomplete due to missing records.

Introduction {#s1}
============

Oral cancer poses a huge challenge to the well-being of people worldwide, and more specifically in the Asian region. Here we define oral cancer as malignant neoplasms of lip, tongue and mouth (OCA). Taken together, these cancers were estimated to affect 354 864 people worldwide in 2018, with 177 384 deaths.[@R1] Fifty-six per cent of the world's oral and pharyngeal cancer burden (excluding nasopharyngeal carcinoma) is from Asia. The incidence of oral cancer for men was estimated at 14.8 per 100 000 population per annum in Globocan 2018. Incidence of oral cancer among men in Sri Lanka was 15.6 per 100 000 population as reported in 2014.[@R2] Oral cancer accounts for nearly 10% of reported cancers with the highest mortality rates of all cancers in Sri Lanka.[@R2]

Both incidence and prevalence approaches have been used to assess the costs of cancer care across the globe. The incidence-based approach assesses the costs of new cases reported in a year and then adds life-time costs. The prevalence-based approach assesses all new and old cases known in a single or particular year. Life-time costs include all expenditures from diagnosis to death. Several examples of the costs of managing head and neck cancer have been published from developed countries: A cross-sectional study from New Zealand reported that cost as NZ\$22 694 per patient.[@R3] In England, the cost of treating oral and oropharyngeal carcinoma was £213 million for a 5 year period. The cost of treatment for oral and oropharyngeal carcinoma in the USA per patient was reported as US\$13 513 for each stage IV case over 3 years.[@R4]

In Sri Lanka 3.5% of Gross Domestic Product is spent on the health budget. Of that, Sri Lankan rupees (SLR) 5945.5 million (2.3% of the current health expenditure) were spent in treating neoplasms.[@R5] Sri Lanka provides a totally free healthcare service to all citizens. There is no published information on the cost of care for OCA patients in Sri Lanka. This study aims to establish this information by conducting a costing exercise within the Sri Lankan health system.

Methods {#s2}
=======

A descriptive cross-sectional study with cost analysis was conducted using activity-based costing with cost apportionment and step-down costing approach. The study was conducted in selected cancer treatment centres in Sri Lanka; the University Dental Hospital Peradeniya (PDH), Apeksha Hospital, Maharagama and Oro-maxillofacial units of General Hospital Kalutara and Kegalle. As both Apeksha Hospital and PDH are centres of excellence for treatment of OCA and treat most of the cases in the nation, it was important to include these two institutions. Two oral and Maxillofacial treatment units were selected randomly from the 25 units across the nation. Sixty nine patients with histopathological confirmation of OCA were selected for study. These patients had squamous cell carcinomas of the oral cavity, arising from the buccal mucosa, retro-molar areas, oral (anterior two-thirds) of the tongue, floor of the mouth, hard palate or lips: these are the common sites, with abuse of areca nut, smokeless and smoked tobacco, and alcohol, often in a background of diets deficient in essential macronutrients and micronutrients as the main risk factors: Human Papilloma Virus-driven cancers are not prominent in these sites in this population.[@R6] Malignancies of the nasopharynx, oropharynx, hypopharynx and other pharynx were excluded.

Trained personal were used for data collection. Patients admitted to the oncology or onco-surgery wards for treatment during the year 2016 were recruited. All patients had a minimum of 1 year follow-up with data being collected throughout a 12-month period. Information regarding the type and stage of the disease, treatment procedures and other related details were obtained from patient records. An interviewer-administered questionnaire was used to collect information from the patients regarding their sociodemographic situation and indirect costs incurred.

The study considered two major types of cost: health system costs and household costs. Health system costs included recurrent and capital costs. Recurrent costs consisted of overhead activities (such as utility and supportive services and administrative personnel), intermediate activities (such as salaries of clinicians, medicines and consumables) and costs associated with clinic visits. Capital costs included land value, buildings and equipment. Apportionment of the times of personnel, equipment depreciation, utility services and supportive services to the activity were derived from discussion with experts in the field: medical specialists and personnel involved in these activities. Cost information of the hospital (salaries, utility and supportive services, equipment purchases and equipment values) were obtained from account ledgers, financial reports, pay sheets and expenditure reports of financial departments of the hospitals. Costs of drugs and consumables were obtained from price lists of the Medical Supplies Division of government. Service-related details were obtained from annual statistical bulletins of the hospitals.

Household costs consisted of direct and indirect costs. Direct costs constituted all the components of out-of-pocket expenditures during the study period for medicines, investigations, travel and food. Indirect costs included opportunity cost for the patient and his/her main carer which were incurred due to clinic visits or hospital days. Opportunity cost per day was calculated by dividing the monthly income of such individuals by days per month (30 days). A standardised data collection form was used to record this information.

Face and content validity were ensured by pilot testing of the checklist and questionnaire in Apeksha Hospital with patients other than OCAs and discussions with experts in the field. Cost data were collected from records in various administrative and financial offices, and from patients when collecting data for household costs. A 10% sample of the questionnaires was rechecked with clinic and BHT records by the first author to enhance the validity and reliability of data.

Data analysis {#s2a}
-------------

The opportunity cost of personnel time per minute was derived by dividing their monthly basic salary by minutes per month \[30 (days) x 24 (hours) x 60 (min)\]. For each intermediate activity, total cost per investigation or procedure was calculated and for each final activity (Clinic, Ward and ICU) cost per patient per day was calculated. Finally, for each patient, a list of final and intermediate activities and number of times that the patient underwent each activity for a period of 12 months were listed using a standard data collection format. The patient cost was the cumulative cost of all these activities. Patients were interviewed to obtain out of pocket expenditure, transport costs, and other indirect costs. Total costs per patient per day, for patients diagnosed with different stages of OCA, were calculated separately. Costs for inward patients and OPD patients who attended review clinics were derived separately.

Patients and public involvement {#s2b}
-------------------------------

Patients were not involved in the development of the research questions and design stage of the study. Overall results were returned to patients during the quarterly meetings of the 'Voice of Blue Pea' Patient Group which is an oral cancer victim group established in the main cancer treatment centres in Sri Lanka.

Results {#s3}
=======

Of 69 OCA patients, 60 were male. Age ranged from 40 to 81 years and 78% of the patients were less than 60 years of age. Most (66%) patients were from disadvantaged backgrounds. Twelve patients had presented with recurrence. Only six OCA patients were in stage II, the remainder being stage III and IV ([table 1](#T1){ref-type="table"}). Eighty per cent of the OCA patients reporting to these cancer treatment centres were chewers of betel quid, 48% were smokers and 67% were consuming alcohol regularly. Among the areca nut/betel-chewing patients, the mean number of quids chewed was 6.9 quids per day (range 0--25); mean number of cigarettes and/or Bidi sloked was four per day (range 0--25).

###### 

Sociodemographic characteristics OCA patients

  -----------------------------------------------------------------------------------------------
  Characteristics                                                     OCA patients   Percentage
  ------------------------------------------------------------------- -------------- ------------
  Sex                                                                                

   Male                                                               60             87.0

   Female                                                             9              13.0

  Age                                                                                

   Years 40--50                                                       17             24.6

   50 -- 60                                                           30             43.5

   60 -- 70                                                           12             17.4

   Above 70  years                                                    10             14.5

  Education                                                                          

   No formal education                                                7              10.1

   Up to general certificate of education (GCE) ordinary/level exam   55             79.7

   GCE advanced level and\                                            7              10.1
   postgraduate                                                                      

  Stage of diagnosis                                                                 

   Stage II                                                           6              8.7

   Stage III                                                          37             53.7

   Stage IV                                                           26             37.7

  Recurrences                                                         12             17.4

  Total                                                               69             100
  -----------------------------------------------------------------------------------------------

OCA, oral cancer.

The present study also assessed the average monthly income and average expenditure on presumptively deleterious lifestyle habits. Average monthly income of the OCA patients was SLR 20 669 (US\$138) and SLR 3003 (US\$20) was spent on betel quid chewing monthly ([table 2](#T2){ref-type="table"}). On average, a total of SLR 10 299 (US\$69) was spent monthly by each of the 40% of patients who practiced these habits. This amounts to approximately half of each patient's average monthly income.

###### 

Average monthly income and money spent on habits by OCA patients

  --------------------------------------------------------------------------------------
  Monthly income and expenditure for lifestyle habits     Amount in SLR (range in SLR)
  ------------------------------------------------------- ------------------------------
  Monthly income                                          

   Average patient monthly income                         20 669 (800--150 000)\
                                                          (US\$138)

   Patients household average monthly income              24 728 (4000--150 000)\
                                                          (US\$165)

  Average expenditure for habits                          

   Monthly expenditure for areca nut/betel quid chewing   3003 (300--10 740)\
                                                          (US\$20)

   Monthly expenditure for tobacco smoking                3214 (0--10 500)\
                                                          (US\$21)

   Monthly expenditure for consumption of alcohol         4082 (0--22 400)\
                                                          (US\$27)
  --------------------------------------------------------------------------------------

OCA, oral cancer; SLR, Sri Lankan rupees.

The mean cost of managing a stage II oral cancer patient was SLR 136 628 ([table 3](#T3){ref-type="table"}). The highest portion of this was the health system cost. Direct and indirect household cost was higher than the health system cost. A patient had to bear about 28% of the total cost paying as out of pocket expenditure and 41% total cost as direct treatment-related expenses.

###### 

The health system cost and household cost of managing single stage II oral cancer patient for 1 year

  Cost category                             Item                       Cost in SLR
  ----------------------------------------- -------------------------- -------------------
  System                                                               
  Recurrent cost                            Clinic visit               273
  Biopsy                                    1399                       
  Dental extraction                         337                        
  X-ray                                     532                        
  Scan                                      255                        
  Lab                                       636                        
  Ward management                           7983                       
  Surgery                                   41 946                     
  Surgery consumables                       202                        
  Follow-up clinic visit                    3000                       
  Staff overhead cost                       527                        
  Total                                     57 091 (US\$381)           
  Capital cost                              Land                       145
  Building                                  158                        
  Furniture                                 1585                       
  Total                                     1888 (US\$13)              
  Household cost                                                       
  Direct cost (Out Of Pocket Expenditure)   Medicines/investigations   18 200
  Travel                                    11 249                     
  Food                                      8839                       
  Total                                     38 287 (US\$256)           
  Indirect costs                            Patient_stay home          8858
  Patient_ward days                         8176                       
  Patient clinic                            8176                       
  Carer cost ward                           7840                       
  Companion clinic visit                    6311                       
  Total                                     39 362 (US\$263)           
  Total cost                                                           136 629 (US\$912)

SLR, Sri Lankan rupees.

Cost of managing stage a 111 and 1V patient with oral cancer was higher than a stage II patient. The total cost per patient was SLR 375 551([table 4](#T4){ref-type="table"}). The highest cost portion was borne by the health system. The out-of-pocket cost for the patient was 8.7% of the total cost.

###### 

The health system cost and household cost of managing a single stage III and IV oral cancer patient for 1 year

  Cost category                             Item                       Cost in SLR
  ----------------------------------------- -------------------------- --------------------
  System cost                                                          
  Recurrent cost                            Clinic visit               273
  Biopsy                                    1399                       
  Dental extractions                        337                        
  Dental restorations                       415                        
  X-ray                                     532                        
  Scan                                      255                        
  CT scan                                   1094                       
  Lab                                       1062                       
  Ward management                           7983                       
  Surgery                                   50 383                     
  Surgery consumables                       190                        
  ICU ward management                       113 782                    
  ICU investigation                         998                        
  Radiotherapy                              55 818                     
  Chemotherapy                              63 683                     
  Follow-up clinic visit                    3000                       
  Staff overhead cost                       527                        
  Total                                     301 731 (US\$2011)         
  Capital cost                              Land                       145
  Building                                  158                        
  Furniture                                 1585                       
  Total                                     1888 (US\$13)              
  Household cost                                                       
  Direct cost (Out Of Pocket Expenditure)   Medicines/investigations   12 059
  Travel                                    10 126                     
  Food                                      10 385                     
  Total                                     32 570 (US\$217)           
  Indirect costs                            Patient stay home          8858
  Patient_ward days                         8176                       
  Patient clinic                            8176                       
  Carer cost ward                           7840                       
  Companion clinic visit                    6311                       
  Total                                     39 362 (US\$263)           
  Total cost                                                           375 551 (US\$2507)

SLR, Sri Lankan rupees.

Discussion {#s4}
==========

This is the first study in calculating cost of OCA in the South Asian region where oral cancer is highly prevalent. We found very high out-of- pocket costs for all patients, most of whom are from low socioeconomic backgrounds. The methodology developed in this study can be of relevance to similar economies in calculating cost of any diseases.

Compared with the other cancers, OCA is a preventable cancer because of its strong association with habits of areca nut/betel quid chewing, tobacco use and alcohol misuse. The majority of OCAs which present in low and Middle Income countries arise from a potentially malignant disorder. Unfortunately, most patients with OCA present with advanced disease.[@R7] Every year around 1500--2000 new cases of OCA are diagnosed in Sri Lanka,[@R2] where almost all patients then receive treatment from State hospitals. As the country has universal free health services, costs are borne by government. In addition, the patient and his/her immediate family have to bear many indirect costs which can be catastrophic for them. To date, no proper cost analysis has been done in the country to identify the actual direct and indirect cost for the management of OCA and to compare it with preventive measures to identify the cost effectiveness.

The study attempted to calculate total costs of management of different stages of OCA for the first time in Sri Lanka. The hospital records of many of these patients were incomplete, and no billing system was in place in the hospitals. Use of advanced investigations, types of surgeries performed, use of radiotherapy and chemotherapy, vary from centre to centre, and operator to operator. Facilities in State sector hospitals are severely limited, leading to suboptimal use of diagnostic and staging investigations, and many of the treatment modalities used may have been far from international standard. Costs derived may not represent ideal outcomes from the patient perspective, but reflect the actual situation in the nation. Many costs may have been underestimated due to the difficulties in collecting accurate information from hospital records. Similar difficulties have been reported by others in collecting accurate cost data.[@R8]

For a patient with stage II OCA, system cost of management was approximately SLR 58 979 (US\$93.72) and household cost around SLR 77 649 (US\$518). For a patient with stage III or IV disease, system cost was around SLR 303 620 (US\$2027) and household cost around SLR 71 932 (US\$480). We did not encounter cases with stage I OCA for cost analysis but can reasonably assume that it is less than stage II cases. This finding is consistent with the findings of other similar studies.[@R8] Our results highlight the importance of early diagnosis of oral cancer, not only to improve survival and the patient's quality of life, but also to minimise costs to the health system.

In Greece in 2002, the average cost of treatment for a patient with OCA was estimated to be US\$7450 (\~SLR 1 200 000)[@R8] whereas in the Netherlands in 2001, it was US\$ 22 080 (SLR 3 315 000)[@R10] and in the USA in 1998, it was reported as US\$32 500 (around SLR 4 875 000).[@R11] In the present study, the average cost for management of OCA was much lower, \~SLR 350 000 (\~US\$2300). In India,[@R12] average treatment cost for OCA was calculated at \~146 000 Indian rupees (\~SLR 375 000 or US\$2400), similar to our values, although the majority of patients in the Indian study were stages 1 and 11. Advanced rehabilitation of surgically treated patients, such as dental and facial prostheses were not provided to this cohort of patients. If the nation can move to provide such services, much higher costs will be incurred.

Conclusion {#s5}
==========

The cost of management of OCA patients in Sri Lanka is extremely high, in relation to mean per capita income and national Gross Domestic Product. This has negative impacts on both the healthcare system and on individual families and impacts the national economy. Most patients affected by this devastating disease are in low socioeconomic category, burdening their families with catastrophic financial consequences. Early identification can reduce the cost of management of OCA significantly. Policy-makers should take note of this burden and take immediate and effective steps to improve primary prevention and early detection of OCA.
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